Venable·IP / PATENT
Venable maps the November 2026 wave of pending biosimilar litigations
Venable's November 2026 "Spotlight On" catalogues pending U.S. biosimilar disputes involving CDER-listed reference-product sponsors and competing applicants — a docket watch for Hatch-Waxman and BPCIA counsel.
biosimilarhatch-waxmanbpciapatent-litigationfda-cder
Read the original firm alert → Tuesday, November 10, 2026